Cargando…

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation

The cardiovascular safety profile of dapoxetine, a novel selective serotonin reuptake inhibitor (SSRI) developed as an on-demand oral treatment for premature ejaculation (PE) in men, is evaluated. The cardiovascular assessment of dapoxetine was conducted throughout all stages of drug development, wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kowey, Peter R., Mudumbi, Ramagopal V., Aquilina, Joseph W., DiBattiste, Peter M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2012
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585760/ https://www.ncbi.nlm.nih.gov/pubmed/21410293 http://dx.doi.org/10.2165/11587660-000000000-00000

Ejemplares similares

Dapoxetine and premature ejaculation
Publicado: (2023)

Emerging treatments for premature ejaculation: focus on dapoxetine
por: Hellstrom, Wayne JG
Publicado: (2009)

Premarket Safety and Efficacy Studies for ADHD Medications in Children
por: Bourgeois, Florence T., et al.
Publicado: (2014)

Global position paper on cardiovascular regenerative medicine
por: Fernández-Avilés, Francisco, et al.
Publicado: (2017)

Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic
por: Asukai, Yumi, et al.
Publicado: (2021)

Safety of International Professional Sports Competitions During the COVID-19 Pandemic: The Association Football Experience
por: Caniza, Horacio, et al.
Publicado: (2022)

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo
por: Cannon, Christopher P, et al.
Publicado: (2008)

UK Biobank: opportunities for cardiovascular research
por: Littlejohns, Thomas J, et al.
Publicado: (2019)

Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
por: Boden, William E, et al.
Publicado: (2020)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention
por: Mortensen, Martin Bødtker, et al.
Publicado: (2017)

Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients
por: Napoli, Claudio, et al.
Publicado: (2020)

Artificial Intelligence and the Future of the Drug Safety Professional
por: Danysz, Karolina, et al.
Publicado: (2018)

Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
por: Bello, Alfonso E., et al.
Publicado: (2014)

Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Assessing the Safety of COVID-19 Vaccines: A Primer
por: Petousis-Harris, Helen
Publicado: (2020)

The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology
por: Kirchhof, Paulus, et al.
Publicado: (2014)

Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many
por: Cadogan, Cathal A., et al.
Publicado: (2015)

Black Swan Events and Intelligent Automation for Routine Safety Surveillance
por: Kjoersvik, Oeystein, et al.
Publicado: (2022)

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis
por: Scigliano, Giulio, et al.
Publicado: (2013)

Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
por: Pimentel, Franklin Fernandes, et al.
Publicado: (2018)

Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
por: Fialkow, Jonathan
Publicado: (2016)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
por: Rajasimhan, Suraj, et al.
Publicado: (2020)

A Structured Methodology to Assess Safety Signal Strength and Inform Causality Assessment
por: Sullivan, Tim, et al.
Publicado: (2022)

ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery
por: Thielmann, Matthias, et al.
Publicado: (2017)

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
por: Smit, Cornelis, et al.
Publicado: (2020)

A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials
por: Patera, Andriani C., et al.
Publicado: (2023)

Dapoxetine and the treatment of premature ejaculation
por: Sangkum, Premsant, et al.
Publicado: (2013)

The Patient’s Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization
por: Smith, Meredith Y., et al.
Publicado: (2016)

Pushing boundaries of video review in trauma: using comprehensive data to improve the safety of trauma care
por: Nolan, Brodie, et al.
Publicado: (2020)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Quality markers in cardiology: measures of outcomes and clinical practice—a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery
por: López-Sendón, José-Luis, et al.
Publicado: (2016)

Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: A joint statement by the European Society of Cardiology, the Council on Hypertension of the European Society of Cardiology, the European Society of Hypertension, the International Society of Mountain Medicine, the Italian Society of Hypertension and the Italian Society of Mountain Medicine
por: Parati, Gianfranco, et al.
Publicado: (2018)

Profiling of Patients with COPD for Adequate Referral to Exercise-Based Care: The Dutch Model
por: Spruit, Martijn A., et al.
Publicado: (2020)

Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis
por: Corrado, Domenico, et al.
Publicado: (2020)

Should Heartbeats/Training Session Be Considered When Comparing the Cardiovascular Benefits of High-Intensity Interval Aerobic and Moderate-Intensity Continuous Training? A Critical Appraisal
por: Rodrigues, Jhennyfer Aline Lima, et al.
Publicado: (2020)

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
por: Borén, Jan, et al.
Publicado: (2020)

Malaria and Economic Evaluation Methods: Challenges and Opportunities
por: Drake, Tom L., et al.
Publicado: (2017)

Recommendations for Face Coverings While Exercising During the COVID-19 Pandemic
por: Shurlock, Jonathan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ujgppf71qo9tdo60htntda1s16